433 related articles for article (PubMed ID: 34249014)
1. Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-
Haring E; Zeiser R; Apostolova P
Front Immunol; 2021; 12():705342. PubMed ID: 34249014
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Interferons on Allogeneic T Cell Response in GVHD: The Multifaced Biology and Epigenetic Regulations.
Zhao C; Zhang Y; Zheng H
Front Immunol; 2021; 12():717540. PubMed ID: 34305954
[TBL] [Abstract][Full Text] [Related]
3. Acute Graft-versus-Host Disease: Novel Biological Insights.
Teshima T; Reddy P; Zeiser R
Biol Blood Marrow Transplant; 2016 Jan; 22(1):11-6. PubMed ID: 26453971
[TBL] [Abstract][Full Text] [Related]
4. Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis.
Rabian F; Porcher R; Sicre de Fontbrune F; Lioure B; Laplace A; Nguyen S; Tabrizi R; Vigouroux S; Tomowiak C; Maillard N; Suarez F; Delage J; Peffault de Latour R; Socié G;
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1721-1724. PubMed ID: 27246370
[TBL] [Abstract][Full Text] [Related]
5. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
6. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
Iliopoulou BP; Hsu K; Pérez-Cruz M; Tang SW; Pang WW; Erkers T; Kambham N; Freeman GJ; Dekruyff RH; Meyer EH
Blood Adv; 2019 Nov; 3(21):3419-3431. PubMed ID: 31714958
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease.
Fløisand Y; Lundin KEA; Lazarevic V; Kristiansen JD; Osnes LTN; Tjønnfjord GE; Reims HM; Gedde-Dahl T
Biol Blood Marrow Transplant; 2017 Jan; 23(1):172-175. PubMed ID: 27777142
[TBL] [Abstract][Full Text] [Related]
9. Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.
Nalle SC; Turner JR
Mucosal Immunol; 2015 Jul; 8(4):720-30. PubMed ID: 25943273
[TBL] [Abstract][Full Text] [Related]
10. Complications Following Stem Cell Therapy in Inflammatory Bowel Disease.
Wei H; Liu X; Ouyang C; Zhang J; Chen S; Lu F; Chen L
Curr Stem Cell Res Ther; 2017; 12(6):471-475. PubMed ID: 28302045
[TBL] [Abstract][Full Text] [Related]
11. Resolution of acute intestinal graft-versus-host disease.
Thiagarajan S; Neurath MF; Hildner K
Semin Immunopathol; 2019 Nov; 41(6):655-664. PubMed ID: 31673757
[TBL] [Abstract][Full Text] [Related]
12. Targeting Inflammatory T Helper Cells
Buchele V; Abendroth B; Büttner-Herold M; Vogler T; Rothamer J; Ghimire S; Ullrich E; Holler E; Neurath MF; Hildner K
Front Immunol; 2018; 9():1138. PubMed ID: 29910804
[TBL] [Abstract][Full Text] [Related]
13. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
14. Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography.
Stelljes M; Hermann S; Albring J; Köhler G; Löffler M; Franzius C; Poremba C; Schlösser V; Volkmann S; Opitz C; Bremer C; Kucharzik T; Silling G; Schober O; Berdel WE; Schäfers M; Kienast J
Blood; 2008 Mar; 111(5):2909-18. PubMed ID: 18057227
[TBL] [Abstract][Full Text] [Related]
15. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease.
Cooke KR; Olkiewicz K; Erickson N; Ferrara JL
J Endotoxin Res; 2002; 8(6):441-8. PubMed ID: 12697087
[TBL] [Abstract][Full Text] [Related]
16. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
Sartor RB
Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
[TBL] [Abstract][Full Text] [Related]
17. Intestinal graft-versus-host disease: mechanisms and management.
Takatsuka H; Iwasaki T; Okamoto T; Kakishita E
Drugs; 2003; 63(1):1-15. PubMed ID: 12487619
[TBL] [Abstract][Full Text] [Related]
18. The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation.
Hidaka D; Hayase E; Shiratori S; Hasegawa Y; Ishio T; Tateno T; Okada K; Goto H; Sugita J; Onozawa M; Nakagawa M; Kahata K; Endo T; Hashimoto D; Teshima T
Clin Transplant; 2018 Sep; 32(9):e13361. PubMed ID: 30054935
[TBL] [Abstract][Full Text] [Related]
19. Immunoregulatory effects of RGMb in gut inflammation.
Pérez-Cruz M; Iliopoulou BP; Hsu K; Wu HH; Erkers T; Swaminathan K; Tang SW; Bader CS; Kambham N; Xie B; Dekruyff RH; Freeman GJ; Meyer E
Front Immunol; 2022; 13():960329. PubMed ID: 36420263
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the treatment of graft-versus-host disease.
Iwasaki T
Clin Med Res; 2004 Nov; 2(4):243-52. PubMed ID: 15931364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
